Biotechnology company PepGen Inc. recently reaffirmed its clinical development timeline, clearly stating that it will release research data from the 5 mg/kg dose group in the Freedom-2 clinical trial in the first quarter of 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Finance Minister: Sanae Takaichi is not a "reflationist" and highly respects the independence of the central bank
The Japanese Finance Minister stated that Ms. Komei herself has repeatedly requested her to clarify this position to overseas investors. This statement attempts to dispel the market’s perception that the Komei government interferes with the central bank or pursues a loose monetary policy. Last Wednesday, two committee members nominated by Komei opposed a Bank of Japan interest rate hike, further reinforcing the market’s view that the Japanese government tends to delay rate increases.
HIFI Raises $37M Series A to Build Settlement Rails for Tokenized Money
Report: Anthropic in talks to lease up to 1GW of data center capacity, with related investments of at least 40 billions dollars
According to media reports, Anthropic is considering renting up to 1GW of computing power from Stream Data Centers. The data center developer indicated that deploying a full 1GW of computing power would require an investment of at least 40 billion USD. Anthropic needs to provide financial guarantees for this lease and separately raise funds for the installed chips.
Crypto prices
More
